Human Tumor Antigens and Cancer Immunotherapy

Vigneron, Nathalie

doi:10.1155/2015/948501

Cited by 178 publications

(151 citation statements)

References 190 publications

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…Despite developments in cancer treatment and the introduction of novel drugs, advanced lung cancer remains associated with poor prognosis. Adoptive immunotherapy, as a new approach to treat solid tumors, has been reported to hold great potential compared with other traditional treatments (13)(14)(15)(16)(17)(18)(19)(20). Adoptive CIK cell transfer, as one type of adoptive immunotherapy, has displayed antitumor effects in various malignant tumor types, including NSCLC (17)(18)(19)(20)(21).…”

Section: Cytokine-induced Killer Cell Therapy For Modulating Regulatomentioning

confidence: 99%

Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer

Wang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Previous studies have reported that regulatory T cells (Tregs), which are physiologically engaged in the maintenance of immunological self-tolerance, have a critical role in the regulation of the antitumor immune response. Targeting Tregs has the potential to augment cancer vaccine approaches. The current study therefore aimed to evaluate the role of cytokine-induced killer (CIK) cell infusion in modulating Tregs in patients with non-small cell lung cancer (NSCLC). A total of 15 patients with advanced NSCLC were treated by an infusion of CIK cells derived from autologous peripheral blood mononuclear cells (PBMCs). By using flow cytometry and liquid chip analysis, subsets of T cells and natural killer (NK) cells in peripheral blood, and plasma cytokine profiles in the treated patients, were analyzed at 2 and 4 weeks after CIK cell infusion. Cytotoxicity of PBMCs (n=15) and NK cells (n=6) isolated from NSCLC patients was evaluated before and after CIK cell therapy. Progression-free survival (PFS) and overall survival (OS) were also assessed. Analysis of the immune cell populations before and after treatment showed a significant increase in NK cells (P<0.05) concomitant with a significant decrease in Tregs (P<0.01) at 2 weeks post-infusion of CIK cells compared with the baseline. NK group 2D receptor (NKG2D) expression on NK cells was also significantly increased at 2 weeks post-infusion compared with the baseline (P<0.05). There was a positive correlation between NKG2D expression and the infusion number of CIK cells (P<0.05).

show abstract

Section: Cytokine-induced Killer Cell Therapy For Modulating Regulatomentioning

confidence: 99%

Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer

Wang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…The success of any cancer vaccine depends on the selection of a suitable target antigen and presentation pathway (62). No vaccine currently exists to colorectal cancer.…”

Section: Discussionmentioning

confidence: 99%

Designing a Chimeric Vaccine Against Colorectal Cancer

et al. 2017

View full text Add to dashboard Cite

Background: Colorectal cancer is the major cause of death worldwide. Recently, cancer immunotherapy has been used in cancer prevention and treatment which has led to immune system response to cancerous cells and their elimination. Recent studies were conducted to specifically target tumor marker to design vaccine. Objectives: Here, we designed a vaccine chimeric including CEA and CA19-9 against colorectal cancer. Methods: The construct was analyzed, using bioinformatics tools and servers. The physicochemical properties, structures, antigenicity, stability, MHC binding properties, and ligand-receptor docking of chimeric protein (CE-CA) were predicted. Results:The results showed the structure of CE-CA has suitable form and separates each domain; furthermore, the epitope mapping did not change after combination. Conclusions:The results showed that the construct can be appropriate vaccine against colorectal cancer and could generate potent immune response against this cancer. In silico tools are useful to design vaccine.

show abstract

“…Tumor antigens can be classified as tumor-specific antigens, that result from cancer-germline genes, point mutations, or oncogenic viruses and unique to tumor cells, or tumor-associated antigens (TAAs), which include differentiation antigens and peptides associated with genes overexpressed in tumors. 46,47 Among the large family of TAAs, expression of cancer testis antigens (NY-ESO, MAGE-A3, MAGE-A4, PRAME, and LAGE) occurs in a variety of sarcomas, including synovial sarcomas, myxoid round-cell liposarcoma, osteosarcoma, ES, chondrosarcoma, leiomyosarcoma, and UPS. [48][49][50] Nevertheless, and as expected for such a heterogeneous group of tumors, immunogenicity is not uniform among sarcomas, and can be influenced by the tumor genomic landscape or mutational load.…”

Section: Tumor Antigens and Intrinsic Antigenic Potential In Sarcomasmentioning

confidence: 99%

Development of Checkpoint Inhibitors for Sarcomas

Munhoz¹,

Tap²,

D’Angelo³

2017

Oncology &Amp; Hematology Review (US)

View full text Add to dashboard Cite

Sarcomas comprise a rare and heterogeneous group of malignancies of bone and soft tissue origin. Despite optimal approach, a significant proportion of patients will develop recurrent/metastatic disease. Although advances have been achieved, therapeutic options for these patients are limited and prognosis remains poor. Over the past century, the characterization of mechanisms involved in the interaction between tumor cells and the immune system has paved the way for the development of different forms of cancer immunotherapy, including cytokines, vaccines, cell therapies, and, more recently and successfully, monoclonal antibodies against molecules involved in the modulation of immune response, or immune checkpoint inhibitors. While the clinical applicability of this approach has been limited in sarcomas, the immunogenic potential of this group of malignancies was demonstrated more than 100 years ago. In this article, we review aspects associated with the immunogenicity of sarcomas and how the use of checkpoint inhibitors is being explored for this group of patients.

show abstract

Human Tumor Antigens and Cancer Immunotherapy

Cited by 178 publications

References 190 publications

Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer

Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer

Designing a Chimeric Vaccine Against Colorectal Cancer

Development of Checkpoint Inhibitors for Sarcomas

Contact Info

Product

Resources

About